dc.contributorUniversity Medical Center Ljubljana
dc.contributorUniversity of Florence
dc.contributorUniversity of Barcelona
dc.contributorUniversity of Genoa
dc.contributorUniversity of Milan
dc.contributorIRCCS Istituto Auxologico Italiano
dc.contributorHospital Sor Maria Ludovica, La Plata
dc.contributorUniversidade do Estado do Rio de Janeiro (UERJ)
dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Federal do Rio de Janeiro (UFRJ)
dc.contributorUniversity of Toronto
dc.contributorState University Hospital Rigshospitalet
dc.contributorTartu University Hospitals
dc.contributorMedizinische Hochschule Hannover
dc.contributorSheba Medical Center
dc.contributorTel Aviv University
dc.contributorKaplan Medical Center
dc.contributorSapir Medical Center
dc.contributorSchneider Children's Medical Center of Israel
dc.contributorHadassah Hebrew University Hospital
dc.contributorUniversita' Cattolica Sacro Cuore
dc.contributorUniversita di Padova
dc.contributorUniversita di Firenze
dc.contributorUniversity Pediatric Clinic
dc.contributorInstitute of Rheumatology
dc.contributorDokuz Eylul University Faculty of Medicine
dc.contributorAnkara Numune Education and Research Hospital
dc.contributorAnkara University School of Medicine
dc.contributorMayo Clinic
dc.contributorUniversity of California Davis Medical Center
dc.date.accessioned2014-05-27T11:23:57Z
dc.date.available2014-05-27T11:23:57Z
dc.date.created2014-05-27T11:23:57Z
dc.date.issued2009-08-25
dc.identifierLupus, v. 18, n. 10, p. 894-899, 2009.
dc.identifier0961-2033
dc.identifierhttp://hdl.handle.net/11449/71115
dc.identifier10.1177/0961203309106917
dc.identifier2-s2.0-68949191174
dc.identifier7098310008371632
dc.identifier0000-0002-7631-7093
dc.description.abstractIn recent years, antiphospholipid syndrome (APS) has been increasingly recognised in various paediatric autoimmune and nonautoimmune diseases, but the relatively low prevalence and heterogeneity of APS in childhood made it very difficult to study in a systematic way. The project of an international registry of paediatric patients with APS (the Ped-APS Registry) was initiated in 2004 to foster and conduct multicentre, controlled studies with large number of paediatric APS patients. The Ped-APS Registry is organised as a collaborative project of the European Forum on Antiphospholipid Antibodies and Juvenile Systemic Lupus Erythematosus Working Group of the Paediatric Rheumatology European Society. Currently, it documents a standardised clinical, laboratory and therapeutic data of 133 children with antiphospholipid antibodies (aPL)-related thrombosis from 14 countries. The priority projects for future research of the Ped-APS Registry include prospective enrolment of new patients with aPL-related thrombosis, assessment of differences between the paediatric and adult APS, evaluation of proinflammatory genotype as a risk factor for APS manifestations in childhood and evaluation of patients with isolated nonthrombotic aPL-related manifestations. © The Author(s), 2009.
dc.languageeng
dc.relationLupus
dc.relation2.969
dc.relation1,410
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectAntiphospholipid antibodies
dc.subjectAntiphospholipid syndrome
dc.subjectPaediatrics
dc.subjectphospholipid antibody
dc.subjectantiphospholipid syndrome
dc.subjectdeep vein thrombosis
dc.subjectgenotype
dc.subjecthuman
dc.subjectpediatrics
dc.subjectprevalence
dc.subjectpriority journal
dc.subjectprognosis
dc.subjectregister
dc.subjectrisk assessment
dc.subjectrisk factor
dc.subjectsingle nucleotide polymorphism
dc.subjectsystemic lupus erythematosus
dc.subjectvein thrombosis
dc.subjectAntiphospholipid Syndrome
dc.subjectChild
dc.subjectHumans
dc.subjectRegistries
dc.subjectThrombosis
dc.titleThe Ped-APS registry: The antiphospholipid syndrome in childhood
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución